EverSource Wealth Advisors’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.27K Buy
772
+115
+18% +$1.26K ﹤0.01% 3082
2025
Q4
$8.16K Buy
657
+397
+153% +$5.28K ﹤0.01% 2901
2025
Q3
$3.73K Buy
260
+139
+115% +$1.9K ﹤0.01% 3281
2025
Q2
$1.49K Sell
121
-36
-23% -$523 ﹤0.01% 3606
2025
Q1
$3.45K Buy
157
+91
+138% +$2.14K ﹤0.01% 2672
2024
Q4
$1.5K Buy
66
+47
+247% +$1.03K ﹤0.01% 2827
2024
Q3
$345 Sell
19
-60
-76% -$1.39K ﹤0.01% 2921
2024
Q2
$1.96K Buy
79
+51
+182% +$1.51K ﹤0.01% 2554
2024
Q1
$817 Sell
28
-86
-75% -$3.44K ﹤0.01% 2634
2023
Q4
$4.96K Sell
114
-57
-33% -$2.24K ﹤0.01% 1862
2023
Q3
$6.53K Buy
171
+63
+58% +$2.65K ﹤0.01% 1587
2023
Q2
$4.44K Buy
108
+97
+882% +$4.67K ﹤0.01% 1778
2023
Q1
$632 Buy
+11
New +$620 ﹤0.01% 2184
2022
Q1
Sell
-17
Closed -$1K 1772
2021
Q4
$1K Buy
+17
New +$1.15K ﹤0.01% 1704

Other funds holding IART

EverSource Wealth Advisors's IART Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Integra LifeSciences (IART) stake by 18% in Q1 2026, buying an estimated $1.26K and bringing the position to 772 shares worth $7.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

EverSource Wealth Advisors first reported a position in IART in Q4 2021 and has held it in 14 quarters since. The position peaked at $8.16K in Q4 2025. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • EverSource Wealth Advisors held 772 shares of Integra LifeSciences worth $7.27K as of Q1 2026.
  • EverSource Wealth Advisors bought 115 Integra LifeSciences shares in Q1 2026, an estimated $1.26K.
  • Integra LifeSciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3082 holding.
  • EverSource Wealth Advisors first reported a position in Integra LifeSciences in Q4 2021 and has held it in 14 quarters since.
  • EverSource Wealth Advisors's Integra LifeSciences position peaked at $8.16K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.